Benzinga·2025-12-25 01:49Market Overview - Wall Street experienced a modest rally with the S&P 500 closing up 0.2%, marking a year-to-date gain of 17% [1] - The Dow Jones Industrial Average rose 0.6% to 48,731.16, while the S&P 500 closed at 6,932.05 and the Nasdaq increased by 0.22% to 23,613.30 [1] Nike Inc. - Nike's stock surged 4.64% to close at $60, with an intraday high of $60.58 and a low of $58.88; the 52-week range is between $82.44 and $52.28 [1] - CEO Tim Cook purchased 50,000 shares of Nike at an average price of $58.97, totaling nearly $3 million, increasing his stake to approximately $6.0 million [2][3] - Nike reported second-quarter revenue of $12.43 billion and earnings per share (EPS) of 53 cents, exceeding estimates, but warned of potential low single-digit revenue decline in the third quarter due to a $1.5 billion annualized tariff headwind and ongoing weakness in China [3] Omeros Corporation - Omeros shares increased by 75.54% to close at $15.36, with an intraday high of $17.65 and a low of $13.92; the 52-week range is $17.65 to $2.95 [4] - The FDA approved Omeros' Yartemlea for treating transplant-associated thrombotic microangiopathy, with studies showing complete response rates of about 61%-68% and 100-day survival rates of roughly 73%-74% [5] Micron Technology Inc. - Micron's shares rose 3.77% to close at $286.68, reaching an intraday high of $289.30 and a low of $277.25; the 52-week range is $289.30 to $61.54 [6] - The company reported first-quarter revenue of $13.64 billion and adjusted earnings of $4.78 per share, driven by its role in artificial intelligence infrastructure, with projected growth in high-bandwidth memory from $35 billion in 2025 to $100 billion by 2028 [7] Intel Corporation - Intel's stock dipped 0.52% to close at $36.16, with an intraday high of $36.17 and a low of $34.95; the 52-week range is between $44.01 and $17.67 [8] - A report indicated that Nvidia paused testing Intel's 18A manufacturing process for advanced AI chips, impacting Intel's efforts to attract major foundry customers [9][10] Dynavax Technologies Corporation - Dynavax shares jumped 38.19% to close at $15.38, with an intraday high of $15.49 and a low of $15.38; the 52-week range is $15.49 to $9.20 [11] - Sanofi announced its acquisition of Dynavax for about $2.2 billion, adding a marketed adult hepatitis B vaccine to its portfolio, with a planned payment of $15.50 per share, representing a 39% premium [12]